Chimeric antigen receptor T cells therapy in solid tumors

Rababah, Fatimah; Alabduh, Taqwa; Awawdeh, AlHareth; Shatnawi, Tareq; Al-Shdaifat, Maha; Ibdah, Elana; Shatnawi, Shatha; AbuZetun, Yahia; Helaly, Ahmed Mohamed; Ghorab, Doaa S

doi:10.1007/s12094-023-03122-8

Cited by 2 publications

(1 citation statement)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their extracellular domain is usually an scFv capable of specifically binding antigens overexpressed at the surface of tumor cells, linked to a hinge domain (e.g., CD8, CD28, IgG1, or IgG4) and a transmembrane domain (e.g., CD28, 4-1BB or CD8), fused to one or more variable intracellular costimulatory domains (e.g., CD28, 4-1BB, or OX40 -not present in first generation CARs) and a CD3ζ activation domain, leading to full T cell activation after contact with the target antigen [27]. CAR-T cell therapy has led to significant advances in cancer cell immunotherapy, resulting in great success in treating hematological malignancies [79], with recent advances for solid tumor treatments [80], including RCC [81].…”

Section: Chimeric Antigen Receptor (Car) T Cellsmentioning

confidence: 99%

Evolution of cell therapy for renal cell carcinoma

Wang,

Suarez,

Kastrunes

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, curative treatment, particularly for advanced-stage disease, remains rare. Cell therapy as a “living drug” has achieved hematological malignancy cures with a high response rate, and significant research efforts have been made to facilitate its translation to solid tumors. Herein, we overview the cellular therapies for RCC focusing on allogeneic hematopoietic stem cell transplantation, T cell receptor gene-modified T cells, chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, lymphokine-activated killer (LAK) cells, γδ T cells, and dendritic cell vaccination. We have also included perspectives for using other recent approaches, such as CAR macrophages, dendritic cell-cytokine induced killer cells and regulatory CAR-T cells to shed light on preclinical development of cell therapy and advancing cell therapy into clinic to achieve cures for RCC.

show abstract